Answer
TAKHZYRO (lanadelumab) is contraindicated in patients with hypersensitivity to lanadelumab or any of the excipients listed in section 6.1.
Sources for this answer
- TAKHZYRO 300 mg solution for injection in pre-filled syringeTakeda UK Ltd · emc · SmPC §4.3 Contraindications · Version 8Document updated
Sources checked